HM17321 (LA-UCN2)_Dosage, benefits & legal status
Also known as HM17321, LA-UCN2
The non-incretin obesity bet: weight loss without the muscle loss, so far only as a design goal.
What is HM17321 (LA-UCN2)?
Plain language first. The technical label stays, but it never stands alone.Overview
What it's used for
An investigational obesity peptide that works outside the GLP-1 pathway, aiming to spare lean mass.
How does HM17321 (LA-UCN2) work?
What it does in the body, and where.Urocortin-2 is a natural 41-residue peptide in the corticotropin-releasing factor family. HM17321 is an engineered long-acting version of it, and the receptor it acts on is the whole point.
- 01It acts on CRF2, not on GLP-1Every approved obesity medicine works through incretin receptors. The developer describes HM17321 as a non-incretin mechanism acting on the corticotropin-releasing factor receptor 2, which is a different pathway entirely.
- 02The lean-mass claim is the reason anyone caresThe licensing announcement describes it as a potential first-in-class treatment designed to promote weight loss and preserve lean body mass at the same time. That is a design intention. No human body-composition result has been published.
- 03Long-acting is an engineering change, not a mechanismThe LA in LA-UCN2 is about how long it lasts in the body. Natural urocortin-2 is cleared quickly, which is why this site's urocortin-2 card describes a research compound given by infusion rather than a weekly injection.
- 04What is actually knownA phase 1 study in healthy volunteers and people with obesity, and a very large licensing deal. Nothing about how much weight it takes off in people, or whether the muscle-sparing idea survives contact with human data.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Chronic weight management, the licensed indicationInvestigational
- Type 2 diabetes and cardiovascular disease, named in the licensing announcement as associated conditionsInvestigational
- Preserving lean body mass during weight loss, which is the design goal and not a demonstrated human effectnone
The published record
Papers about HM17321 (LA-UCN2) · this compound only
Searched: HM17321, LA-UCN2.
1 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
1 registered trials · none with posted results
Furthest stage reached: Phase 1, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

At a glance
Four things to know about HM17321 (LA-UCN2)
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not published
How much, and do you cycle it?
The range, and whether you take breaks.Phase 1 dose levels have not been published, not disclosed. Not established No range
A phase 1 compound with no published dosing schedule. There is nothing to cycle because there is no established way to take it.
Not publishedNo figure
No pharmacokinetic data has been published. Long-acting is in the compound's own development name, which implies a half-life engineered to support infrequent dosing, but no measured figure appears in anything read here. Natural urocortin-2 is cleared quickly, which is the problem the analog exists to solve.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
HM17321 (LA-UCN2) has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Not applicable: this is an investigational compound with no approved use and no published safety profile
- Anyone outside a registered clinical trial, because there is no legitimate supply
Stop and get help
- Not applicable outside a clinical trial, where the protocol and the study doctor govern
Common effects
- None published.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is HM17321 (LA-UCN2) approved?
And where the numbers on this page come from.No. HM17321 (LA-UCN2) is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteInjected; the route is not stated in the documents read here
- Checked17 November 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like HM17321 (LA-UCN2)?
Others in Weight loss and metabolic, side by side.If you're weighing HM17321 (LA-UCN2), it's worth reading HM15275, Pep19 (WATACAP), and Semaglutide in the same class.
The non-incretin obesity bet: weight loss without the muscle loss, so far only as a design goal.
- Dose
- Phase 1 dose levels have not been published
- How often
- Not disclosed
A triple agonist worth watching, with a number that is routinely quoted out of its timeframe.
- Dose
- 0.5 to 8 mg weekly in phase 1; the phase 2 dose levels include amounts above 8 mg and are not individually published
- How often
- Weekly
An oral ten-residue CB1 blocker with two company-funded trials that disagree about weight.
- Dose
- 2 to 10 mg once daily at bedtime (trials)
- How often
- Once daily at bedtime
The drug in Ozempic and Wegovy: a weekly shot that curbs hunger for steady weight loss.
- Dose
- 0.25 up to 2.4 mg per week (start low, increase slowly)
- How often
- Weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Hanmi Pharm, Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy(2026)The developer's own announcement, which is the primary document for everything on this card. Hanmi entered an exclusive licensing agreement with Genentech, a member of the Roche Group, for the development, manufacturing and commercialization of HM17321 (UCN2) for obesity and associated conditions including type 2 diabetes and cardiovascular disease, worldwide excluding South Korea. It describes HM17321 as a proprietary urocortin-2 analog with a non-incretin mechanism of action and a potential first-in-class treatment designed to promote weight loss and preserve lean body mass at the same time. Total deal value up to 2.3 billion dollars including the upfront payment, milestones and tiered royalties on net sales.
- Dailypharm Korea, Hanmi licenses obesity drug candidate to Genentech(2026)Trade reporting that puts a number on the upfront and on the handover. The deal is reported at 2.305 billion dollars in total including a 190 million dollar upfront payment, with Hanmi completing the ongoing phase 1 study before development responsibility transfers to Genentech from phase 2 onward.
Beyond these, 1 records are indexed for this compound. Browse the records
